Cornea

Investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

IKA Keratoconus Symposium and Controversies in Modern Eye Care shone brightly in May

Educational resources include handouts, videos and a dedicated webpage on the proper way to use eye drops

From amniotic membrane grafting to neurotization.

Plasma emission for blepharitis, meibomian gland dysfunction, and dry eye disease.

In this PER On Air Ophthalmology Times podcast, a team of experts provides insights into the diagnosis and management of patients with NK (including assessing their underlying cause of NK), with a look at the range of treatments available for patients with advanced stages of NK.

The adaptor was tested by low-vision patients and participants with simulated visual impairment

Phase 1 multicenter study demonstrates early signs of efficacy.

Optimizing corneal neurotization outcomes with cryopreserved amniotic membrane.

Researchers found that blocking the interaction between peptide and receptor using topical applications of naltrexone reverses dry eye symptoms in 5 days and restores tear fluid volumes to normal baseline.

The NP-1/NP-1C preloaded IOL injector has already been made available in parts of Asia

Two randomized, double-masked, placebo-controlled, Phase 3 trials named REVEAL-1 and REVEAL-2 are expected to start in August 2024.

Plasma emission can act as a therapeutic for blepharitis, dry eye and other ocular disease

According to the company, the treatment option can save time in the operating room and make the most of corneal donations.

The flagship, light-based technology has received approval for applications in the anterior and posterior segments

The high-level analysis found that 82% of TEPEZZA-treated patients in the follow-up did not report needing any additional TED treatment for nearly 2 years.

Challenging choices force ophthalmologists to weigh long-term outcomes

Roy Rubinfeld, MD, MA, discussed EpiSmart cross-linking for keratoconus and the ongoing trials and results at the IKA 2024 Symposium.

At the IKA 2024 Symposium, Michael Belin, MD, discussed the ABCD Progression Display he developed to classify disease severity and help diagnose keratoconus earlier.

Jennifer Harthan, OD, FAAO, FSLS, shared the importance of early diagnostics and pediatric screening of keratoconus at the IKA 2024 Symposium.

Melissa Barnett, OD, Director of Optometry at the University of California, Davis, talked about her session at IKA that focused on keratoconus from the patient perspective.

Elizabeth Yeu, MD, Executive Board Member of IKA, and a cataract and refractive surgeon at Virginia Eye Consultants, talked about perioperative considerations for cataract surgery in keratoconus patients.

Justin Schweitzer, OD, FAAO, from Vance Thompson Vision, talked about his session at the IKA Symposium discussing cross-linking in keratoconus treatment, with a look at both the present and looking toward the future.

Barry Eiden, OD, FAAO, FSLS, President and Co-founder of IKA, talked about his session at the meeting centering around the pediatric prevalence of keratoconus, the importance of early diagnosis, and the impact this can have on practices.